Cartalax
“Cartilage” bioregulator; almost all support is preclinical/regional.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
Cartalax (Ala-Glu-Asp) is presented as a bioregulator for cartilage and connective tissue. External validation is especially weak compared to standard joint therapies.
Studied for
How it works
Khavinson hypothesis: tissue-specific gene regulation in chondrocytes/matrix. Limited independent molecular data.
What the research says
Mentions in bioregulator reviews; few high-impact external papers. There are no large Western RCTs for osteoarthritis.
Evidence level
D
What's most reported
- Claims of joint comfort (anecdotal/regional)
- Laboratory data on connective tissues according to the group
Common side effects
Not characterized in a modern, independent manner.
Combines / does not combine
Does not replace physical therapy, weight loss, or evidence-based joint therapies. Do not invent synergy with BPC-157.
Frequently asked questions
There is no solid human evidence to demonstrate this.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidance. Research products are not approved drugs unless otherwise stated.